Hospira announced that the FDA has approved topotecan injection for the treatment of small cell lung cancer (SCLC) sensitive disease after failure of first-line chemotherapy. Topotecan is the generic of Hycamtin (from GlaxoSmithKline) which is currently available as capsules or as powder for IV infusion after reconstitution and dilution.

Hospira’s topotecan solution for injection will be available at the end of February in a 4mg/4mL concentration.

For more information call (800) 615-0187 or visit www.hospira.com.